Medimap Bio Claims Top Spot at Japan's Shonan iPark 'Innovation Tiger 2025'

Innovative immunotherapy development company Medimap Bio proved its technological prowess on the global stage by winning the prestigious 1st place at the pitching event 'Innovation TIGER 2025' held at Shonan Health Innovation Park in Japan. Medimap Bio, led by CEO Kang Yoo-hoe, competed against 16 finalists selected from 79 startups across three Asian countries including Korea, Japan, and Taiwan, and achieved the glory of final victory on the final pitch day on September 30. With this win, Medimap Bio received prize money of 3 million yen and an invitation to the 'Shonan Health Innovation Conference (SHIC 2025)' to be held in Boston, USA, this November. SHIC is an event that provides 1:1 partnering opportunities with leading global VCs and CVCs, and is expected to become a crucial bridgehead for Medimap Bio's entry into overseas markets and attracting investment. In this pitch, Medimap Bio presented its pipeline of immunotherapies for cancer and autoimmune diseases utilizing its AI-based immunotherapy platform technology, and was particularly highly praised by the judging panel for its unique technological differentiation, excellent efficacy, and safety. The judging panel, comprising 8 global pharmaceutical companies including MSD, Takeda, and Eli Lilly, highly valued Medimap Bio's technological prowess, commercialization potential, and potential for investment and collaborative research. As a resident company of Seoul Bio Hub, a bio/medical startup support platform established by the Seoul Metropolitan Government, Medimap Bio, actively utilizing its infrastructure and support, plans to leverage this award to advance its technology and expand global collaboration opportunities. CEO Kang Yoo-hoe stated that this award is "a great achievement where Medimap Bio's technological prowess and growth potential have been internationally recognized," and expressed strong ambition, saying, "Through SHIC, we will introduce our innovative immunotherapy platform to the world and create opportunities for practical partnering and additional investment attraction." This is expected to be a significant turning point for Medimap Bio to secure a leading position in the global bio market.